Wan-Chen Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wan-Chen Wu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Bo-Ching Lee
National Taiwan University Hospital
3 shared publications - Chin-Chen Chang
Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan
3 shared publications Kuo-How Huang
Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan
3 shared publications- Vin-Cent Wu
Division of Nephrology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
3 shared publications - Yen-Hung Lin
National Taiwan University Hospital
3 shared publications - Cheng-Hsuan Tsai
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
Fibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
Open AccessFibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
- Open Access
Recognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
Open AccessRecognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
- Open Access
Integrative Genomic and Immune Repertoire Profiling Identifies Clonal Signatures Linked to Antithyroid Drug-Induced Agranulocytosis
Graves’ disease (GD) is the leading cause of hyperthyroidism and is often treated with antithyroid drugs (ATDs). Although ATD therapy is effective, it might cause a rare but serious adverse effect called ATD-induced agranulocytosis (TiA), which can lead to severe neutropenia and life-threatening infections. Previous studies have shown that certain human leukocyte antigen (HLA) alleles, including HLA-B*38:02 and HLA-DRB1*08:03 in Asian populations, have been associated with TiA susceptibility. However, the underlying mechanisms remain unclear, highlighting the need to investigate the TiA-related immune alterations to better understand its pathogenesis and mechanisms. In this study, we investigated the immune receptor repertoire in TiA patients. Global repertoire diversity, VJ gene usage, and V-J pairing remained preserved across phenotypes and disease phases. Notably, TiA patients exhibited several upregulated complementarity-determining regions 3 (CDR3) clonotypes compared to GD patients, suggesting their role in disease progression and pathogenesis. Single-cell immune repertoire analysis revealed that TiA-associated risk CDR3 sequences were predominantly expressed on CD8+ effector memory T cells (CD8 TEM) in patients with HLA-B*38:02 , while CD4+ central memory T cells (TCM) showed increased expression of risk CDR3 sequences in patients with HLA-DRB1*08:03 , suggesting distinct cellular mechanisms underlying HLA-associated TiA pathogenesis. In conclusion, this study sheds light on the adaptive immunoprofile associated with TiA development and provides insights into the adaptive immune profile of TiA and HLA-mediated disease susceptibility.
Open AccessIntegrative Genomic and Immune Repertoire Profiling Identifies Clonal Signatures Linked to Antithyroid Drug-Induced Agranulocytosis
Graves’ disease (GD) is the leading cause of hyperthyroidism and is often treated with antithyroid drugs (ATDs). Although ATD therapy is effective, it might cause a rare but serious adverse effect called ATD-induced agranulocytosis (TiA), which can lead to severe neutropenia and life-threatening infections. Previous studies have shown that certain human leukocyte antigen (HLA) alleles, including HLA-B*38:02 and HLA-DRB1*08:03 in Asian populations, have been associated with TiA susceptibility. However, the underlying mechanisms remain unclear, highlighting the need to investigate the TiA-related immune alterations to better understand its pathogenesis and mechanisms. In this study, we investigated the immune receptor repertoire in TiA patients. Global repertoire diversity, VJ gene usage, and V-J pairing remained preserved across phenotypes and disease phases. Notably, TiA patients exhibited several upregulated complementarity-determining regions 3 (CDR3) clonotypes compared to GD patients, suggesting their role in disease progression and pathogenesis. Single-cell immune repertoire analysis revealed that TiA-associated risk CDR3 sequences were predominantly expressed on CD8+ effector memory T cells (CD8 TEM) in patients with HLA-B*38:02 , while CD4+ central memory T cells (TCM) showed increased expression of risk CDR3 sequences in patients with HLA-DRB1*08:03 , suggesting distinct cellular mechanisms underlying HLA-associated TiA pathogenesis. In conclusion, this study sheds light on the adaptive immunoprofile associated with TiA development and provides insights into the adaptive immune profile of TiA and HLA-mediated disease susceptibility.
- 13 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110  (5) , 1419-1426
Cushing Syndrome Is Associated With a Higher Risk of Cancer—A Nationwide Cohort Study
Context: Patients with Cushing syndrome (CS) have higher risk of obesity and diabetes, which are important risk factors of cancers. However, if patients with CS have a higher incidence of cancer remains unknown. Objective: To investigate whether endogenous CS is associated with increased cancer incidence. Methods: A nationwide cohort study analyzing data retrieved from Taiwan's National Health Insurance program in 2006-2017. Between 2006 and 2017, 1278 patients with newly diagnosed endogenous CS were identified. Among them, 1246 patients without a history of malignancy were enrolled in this study. The age- and sex-standardized incidence rate of all-cause cancer and age-, sex-, and calendar year–standardized incidence ratio (SIR) of cancer in association with endogenous CS. Results: The age- and sex-standardized incidences of CS decreased from 4.84 to 3.77 per million person-years between 2006 and 2017. The age at diagnosis of CS was 45.3 ± 14.8 years, and 80.0% of the patients were female. Cushing disease and adrenal CS accounted for 35.4% and 64.6% of patients with CS, respectively. The incidence rate of cancer in patients with CS was 7.77 (95% CI 5.84-10.14) per 1000 person-years, with a SIR of 2.08 (95% CI 1.54-2.75). The 3 most common cancer types were liver (27.7%), kidney (16.7%), and lung (13.0%). Conclusion: Patients with endogenous CS have a higher incidence of cancer.
- 13 June 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110  (5) , 1419-1426
Cushing Syndrome Is Associated With a Higher Risk of Cancer—A Nationwide Cohort Study
Context: Patients with Cushing syndrome (CS) have higher risk of obesity and diabetes, which are important risk factors of cancers. However, if patients with CS have a higher incidence of cancer remains unknown. Objective: To investigate whether endogenous CS is associated with increased cancer incidence. Methods: A nationwide cohort study analyzing data retrieved from Taiwan's National Health Insurance program in 2006-2017. Between 2006 and 2017, 1278 patients with newly diagnosed endogenous CS were identified. Among them, 1246 patients without a history of malignancy were enrolled in this study. The age- and sex-standardized incidence rate of all-cause cancer and age-, sex-, and calendar year–standardized incidence ratio (SIR) of cancer in association with endogenous CS. Results: The age- and sex-standardized incidences of CS decreased from 4.84 to 3.77 per million person-years between 2006 and 2017. The age at diagnosis of CS was 45.3 ± 14.8 years, and 80.0% of the patients were female. Cushing disease and adrenal CS accounted for 35.4% and 64.6% of patients with CS, respectively. The incidence rate of cancer in patients with CS was 7.77 (95% CI 5.84-10.14) per 1000 person-years, with a SIR of 2.08 (95% CI 1.54-2.75). The 3 most common cancer types were liver (27.7%), kidney (16.7%), and lung (13.0%). Conclusion: Patients with endogenous CS have a higher incidence of cancer.
- Open Access
- 17 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S114-S124
Strategies for subtyping primary aldosteronism
- 17 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S114-S124
Open AccessStrategies for subtyping primary aldosteronism
- Open Access
- 11 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S104-S113
The role of confirmatory tests in the diagnosis of primary aldosteronism
- 11 May 2023
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123, S104-S113
Open AccessThe role of confirmatory tests in the diagnosis of primary aldosteronism
- 14 September 2022
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 187  (4) , 519-530
Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics
Objective: Concurrent autonomous cortisol secretion (ACS) in patients with primary aldosteronism (PA) is being reported more frequently. Several somatic mutations including PRKACA, GNAS, and CTNNB1 were identified in cortisol-producing adenomas (CPAs). The presence of these mutations in unilateral PA (uPA) patients concurrent with ACS (uPA/ACS) is not well known. This study aimed to investigate the prevalence of these mutations and their clinical vs pathological characteristics in uPA/ACS. Design: This is a retrospective cohort study. Methods: Totally 98 uPA patients from the Taiwan Primary Aldosteronism Investigation registry having overnight 1-mg dexamethasone suppression test (DST) and adrenalectomy from 2016 to 2018 were enrolled. Their adrenal tumors were tested for PRKACA, GNAS, and CTNNB1 mutations. Results: 11 patients had CPA-related mutations (7 PRKACA and 4 GNAS). The patients carrying these mutations had higher post-DST cortisol (5.6 vs 2.6 μg/dL, P = 0.003) and larger adenoma (2.2 ± 0.3 vs 1.9 ± 0.7 cm, P = 0.025). Adenomas with these mutations had a higher prevalence of non-classical uPA (72.7% vs 26.3%, P = 0.014). Numerically, slightly more complete clinical success of uPA patients with these mutations was noticed after adrenalectomy, although it was statistically non-significant. Post-DST cortisol levels, adenoma size >1.9 cm, and the interaction of adenoma size >1.9 cm with potassium level were found to be associated with the presence of these mutations. Conclusion: Our study showed that CPA-related mutations were detected in 36.7% of uPA/ACS adenomas. The presence of these mutations was associated with higher post-DST cortisol levels, larger adenoma sizes, and a high percentage of non-classical uPA. However, these mutations did not significantly affect the clinical and biochemical outcomes after adrenalectomy of uPA/ACS patients but they showed a better trend.
- 14 September 2022
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 187  (4) , 519-530
Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics
Objective: Concurrent autonomous cortisol secretion (ACS) in patients with primary aldosteronism (PA) is being reported more frequently. Several somatic mutations including PRKACA, GNAS, and CTNNB1 were identified in cortisol-producing adenomas (CPAs). The presence of these mutations in unilateral PA (uPA) patients concurrent with ACS (uPA/ACS) is not well known. This study aimed to investigate the prevalence of these mutations and their clinical vs pathological characteristics in uPA/ACS. Design: This is a retrospective cohort study. Methods: Totally 98 uPA patients from the Taiwan Primary Aldosteronism Investigation registry having overnight 1-mg dexamethasone suppression test (DST) and adrenalectomy from 2016 to 2018 were enrolled. Their adrenal tumors were tested for PRKACA, GNAS, and CTNNB1 mutations. Results: 11 patients had CPA-related mutations (7 PRKACA and 4 GNAS). The patients carrying these mutations had higher post-DST cortisol (5.6 vs 2.6 μg/dL, P = 0.003) and larger adenoma (2.2 ± 0.3 vs 1.9 ± 0.7 cm, P = 0.025). Adenomas with these mutations had a higher prevalence of non-classical uPA (72.7% vs 26.3%, P = 0.014). Numerically, slightly more complete clinical success of uPA patients with these mutations was noticed after adrenalectomy, although it was statistically non-significant. Post-DST cortisol levels, adenoma size >1.9 cm, and the interaction of adenoma size >1.9 cm with potassium level were found to be associated with the presence of these mutations. Conclusion: Our study showed that CPA-related mutations were detected in 36.7% of uPA/ACS adenomas. The presence of these mutations was associated with higher post-DST cortisol levels, larger adenoma sizes, and a high percentage of non-classical uPA. However, these mutations did not significantly affect the clinical and biochemical outcomes after adrenalectomy of uPA/ACS patients but they showed a better trend.